Abstract
In view of a potential clinical use, we assessed the antiproliferative effect of paclitaxel on the human steroid-secreting NCI-H295 adrenocarcinoma cell line. By MTT, paclitaxel induced a dose-dependent inhibition of cell proliferation, with IC50 lower than blood levels of the drug achieved in patients treated for other malignancies. Cell exposure to paclitaxel for 24 h at the different IC50S produced a dose-responsive increase in DNA fragmentation, morphologically confirmed by electron microscopy. A time-dependent decrease in aldosterone, cortisol and testosterone was observed. Paclitaxel is an effective antiproliferative agent in this human adrenocortical carcinoma cell line. Apoptosis induced by the drug in involved in neoplastic cell death. A potential role of the drug in the treatment of patients with adrenocortical cancer could be considered.
Citations
Sep 27, 2001·World Journal of Surgery·A P DackiwD B Evans
Dec 16, 2011·Hormones & Cancer·Michael J DemeureLawrence S Kirschner
Mar 25, 2000·Endocrinology and Metabolism Clinics of North America·C A Stratakis, G P Chrousos
Dec 14, 2011·Annals of Surgery·Michael J DemeureKimberly J Bussey
Dec 23, 2011·European Journal of Endocrinology·Alfredo BerrutiMassimo Terzolo
Jan 8, 2011·The Oncologist·Lyndal J TaconStan B Sidhu
Feb 18, 2014·Endocrine-related Cancer·Constanze HantelFelix Beuschlein
Feb 25, 2015·International Journal of Oncology·Lidia CerquettiAntonio Stigliano
Sep 20, 2011·Molecular and Cellular Endocrinology·Tao Wang, William E Rainey
Feb 21, 2004·Biochemical and Biophysical Research Communications·Eunyoung Chun, Ki-Young Lee
Nov 26, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Catia PilonFrancesco Fallo
Feb 25, 2010·Anesthesiology·Joseph F CottenDouglas E Raines
May 9, 2013·British Journal of Cancer·T UrupG Daugaard
Sep 20, 2019·Molecular and Cellular Endocrinology·Martina FragniSandra Sigala
Jun 28, 2001·Current Problems in Surgery·J A NortonH N Le